Cancer Drug's Long-Term survival effects under scrutiny in major extension trial
NCT ID NCT07405164
Summary
This study follows patients who are already taking the cancer drug belzutifan in earlier trials. Researchers want to understand the long-term survival benefits and safety of this medication for people with advanced solid tumors or tumors related to Von Hippel-Lindau disease. Only participants currently receiving belzutifan in specific previous studies are eligible to join this extension phase.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON HIPPEL LINDAU DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
START San Antonio ( Site 0104)
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-••••
-
Samsung Medical Center ( Site 2902)
RECRUITINGGangnam, Seoul, 06351, South Korea
Contact Phone: •••-•••-••••
-
Severance Hospital, Yonsei University Health System ( Site 2901)
RECRUITINGSeodaemun-gu, Seoul, 03722, South Korea
Contact Phone: •••-•••-••••
-
Taipei Veterans General Hospital ( Site 2800)
RECRUITINGTaipei, 11217, Taiwan
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.